Ondine Biomedical (LON:OBI) Shares Down 2.4% – Should You Sell?

Ondine Biomedical Inc. (LON:OBI) shares traded down 2.4% on Friday . The stock traded as low as C$13.05 and last traded at C$13.43. 450,866 shares were traded during trading, an increase of 4% from the average daily volume of 434,064 shares. The stock had previously closed at C$13.75.

Ondine Biomedical Stock Performance

The company has a quick ratio of 8.26, a current ratio of 1.23 and a debt-to-equity ratio of 11.85. The stock has a fifty day moving average of C$14.28 and a 200-day moving average of C$11.98. The stock has a market cap of C$6.97 billion, a PE ratio of -1.92 and a beta of 0.32.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.